Nonlinear pharmacokinetics: clinical Implications.

作者: Thomas M. Ludden

DOI: 10.2165/00003088-199120060-00001

关键词:

摘要: Nonlinear pharmacokinetics (in other words, time or dose dependences in pharmacokinetic parameters) can arise from factors associated with absorption, first-pass metabolism, binding, excretion and biotransformation. Nonlinearities absorption bioavailability cause increases drug concentrations that are disproportionately high low relative to the change dose. One of more important sources nonlinearity is partial saturation presystemic metabolism exhibited by such drugs as verapamil, propranolol hydralazine. In cases, circulating sensitive not only size but also rate absorption: slower may decrease overall systemic availability. The binding plasma constituents, blood cells extravascular tissue exhibit concentration dependence. This parameters based on total serum be concentration-dependent. Often, these free appear linear. An consideration regard concentration-dependent difficulty relating a usual therapeutic range if better indicator effect. Measurement needed particularly intersubject variability high. example this behaviour valproic acid. Partial elimination pathways result well known typical Michaelis-Menten pharmacokinetics. Small changes dosing make much larger differences steady-state concentration. achieve given fraction becomes longer approaches maximum rate. Alcohol phenytoin examples behaviour. sensitivity cumulation both influenced magnitude parallel first-order pathways: even pathway 1 2% clearance (which occurs at very concentration) an determinant when Theophylline salicylate have significant saturable pathways. Autoinduction causes increase long term administration. some dosage adjustment must made compensate for increase, possibility degree induction dose- kept mind. Carbamazepine major autoinduction. It fortunate few many hundreds use nonlinear leads clinical implications.(ABSTRACT TRUNCATED AT 400 WORDS)

参考文章(136)
Marcus M. Reidenberg, Dennis Drayer, Ann L. DeMarco, Carmen T. Bello, Hydralazine elimination in man. Clinical Pharmacology & Therapeutics. ,vol. 14, pp. 970- 977 ,(1973) , 10.1002/CPT1973146970
S Pynnönen, M Sillanpää, H Frey, The auto-induction of carbamazepine during long-term therapy International journal of clinical pharmacology, therapy, and toxicology. ,vol. 18, pp. 247- 252 ,(1980)
Gillespie Ng, Cotzias Gc, Bell Ma, Mena I, Diets affecting treatment of parkinsonism with levodopa. Journal of The American Dietetic Association. ,vol. 62, pp. 525- ,(1973)
Peter H. Hinderling, Edward R. Garrett, Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans Journal of Pharmacokinetics and Biopharmaceutics. ,vol. 4, pp. 199- 230 ,(1976) , 10.1007/BF01063614
ND Bax, GT Tucker, HF Woods, Lignocaine and indocyanine green kinetics in patients following myocardial infarction. British Journal of Clinical Pharmacology. ,vol. 10, pp. 353- 361 ,(1980) , 10.1111/J.1365-2125.1980.TB01771.X
William D. Ensminger, Suzette C. Walker-Andrews, Ira S. Wollner, Michael K. Cochran, John W. Gyves, Philip L. Stetson, John G. Wagner, Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Research. ,vol. 46, pp. 1499- 1506 ,(1986)
Daniel E. Furst, Niroo Gupta, Harold E. Paulus, Salicylate Metabolism in Twins: EVIDENCE SUGGESTING A GENETIC INFLUENCE AND INDUCTION OF SALICYLURATE FORMATION Journal of Clinical Investigation. ,vol. 60, pp. 32- 42 ,(1977) , 10.1172/JCI108766
H Boudoulas, J J Lima, M Blanford, Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics. Journal of Pharmacology and Experimental Therapeutics. ,vol. 219, pp. 741- 747 ,(1981)